A Randomized, Double Blinded, Phase IIb/III, Decentralized Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Participants With Mild to Moderate Acne Vulgaris

Trial Profile

A Randomized, Double Blinded, Phase IIb/III, Decentralized Study of B244 Delivered as a Topical Spray to Determine Safety and Efficacy in Participants With Mild to Moderate Acne Vulgaris

Completed
Phase of Trial: Phase II/III

Latest Information Update: 24 Jul 2017

At a glance

  • Drugs B 244 (Primary)
  • Indications Acne vulgaris
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AOBiome
  • Most Recent Events

    • 20 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 27 Jun 2017 Planned primary completion date changed from 1 May 2017 to 15 Jul 2017.
    • 17 Mar 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top